TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04026321
Drug: SQ001 500mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ001 500mL/day will be administered by intravenous route at a rate of 3 mL/minute
Study: NCT04026321
Drug: SQ001 625mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ001 625mL/day will be administered by intravenous route at a rate of 3 mL/minute
Study: NCT04026321
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% will be administered by intravenous route at a rate of 3 mL/minute
Study: NCT02867267
Drug: Thymosin alpha 1
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of 1.6 mg thymosin alpha 1 every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
Study: NCT02020616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04282252
Drug: I.V. SOLUTIONS
Normalized name: I.V. SOLUTIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All i.v. fluids used in an Intensive Care Unit.
Study: NCT01165983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0mg tablet, taken orally for 12 weeks daily
Study: NCT00974753
Drug: Ketorolac 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
Study: NCT01071993
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
Study: NCT00305695
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01117181
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.
Study: NCT00920244
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to guidelines epinephrine 1 mg i.v. is administered every 3 minutes during cardiopulmonary resuscitation.
Study: NCT02177318
Drug: Spiriva (tiotropium bromide) inhalation capsules
Normalized name: Spiriva Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
Study: NCT05112354
Drug: systemic and intratympanic injection of steoid
Normalized name: Betagen brand of Betamethasone and Gentamicin Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: -If the patient come at first two weeks of onset of hearing loss the patient will be manged by oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.~2-Patient will be manged by 5 sessions of intratympanic steroid after failure of systemic steroid and patient who come after 2 weeks of onset of hearing loss , each session will be 3 days apart. The injectable material will be 1ml of hydrocortisone 8ml. The injection will be done under local anesthesia and microscope magnification. A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia by using insulin syringe 1ml bore.~An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM All patients will receive antiviral therapy in the form of acyclovir,valcyclovir All the patient will receive vasodilator.
Study: NCT03579940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01487135
Drug: EVP-6124
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral low dose of EVP-6124 in cranberry juice (180 mL) administered on Day 1 and a high dose of EVP-6124 in cranberry juice (180 mL) administered on Day 2.
Study: NCT01487135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice only (180 mL) administered orally on both Day 1 and Day 2.
Study: NCT00303836
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01132807
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00786006
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
Study: NCT01132807
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01132807
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo radiation therapy
Study: NCT03202407
Drug: Calcium acetate and sevelamer hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: receive the conventional renal replacement therapy including calcium-based phosphate (calcium acetate) and active form of vitamin D for 3 months with regular follow up of serum phosphate ,calcium, parathyroid hormone and alkaline phosphate every month
Study: NCT03624166
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive 3 ml of isotonic saline after spinal anesthesia
Study: NCT01751984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 8 weeks
Study: NCT02430090
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: this used in intratechal area and for spinal anesthesia in ceserean section
Study: NCT02430090
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: this used in intratechal area and for spinal anesthesia in ceserean section
Study: NCT02911870
Drug: SNAC
Normalized name: Glucerna Snack Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT02911870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT03512171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One oral dose of placebo to estimate D2 receptor levels at baseline with PET imaging (necessary to calculate dopamine release in the amphetamine condition).
Study: NCT00725777
Drug: artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard artemether-lumefantrine treatment
Study: NCT04148534
Drug: Rocroniom, Non Depolarizing Muscle Relaxant
Approvals — FDA: no, EMA: no, PMDA: no
Description: compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery
Study: NCT01460563
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline as same dose as MgSO4 as placebo
Study: NCT00382161
Drug: Fluvastatin-sodium
Normalized name: Fluvastatin Sodium
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01979380
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, once in the morning
Study: NCT02561871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
Study: NCT03802032
Drug: KY jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical KY jelly
Study: NCT00785863
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo IV and remifentanil infusion
Study: NCT00785863
Drug: Parecoxib and remifentanil
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib IV and remifentanil infusion
Study: NCT03887624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
Study: NCT01066923
Drug: Daily placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator for daily aspirin therapy
Study: NCT01066923
Drug: Acute placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator for acute aspirin therapy
Study: NCT04390958
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1750mg/m2 po bid d1-14
Study: NCT00824473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01509755
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily injection, under the skin (s.c.) for 12 weeks
Study: NCT02269904
Drug: Fluorouracil Implants
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
Study: NCT02269904
Drug: Xelox regimes
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
Study: NCT01453140
Drug: Cyclophosphamide and Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: On the first day of treatment, cyclophosphamide will be administered at a dose of 4g/m2 IV x 1 dose. Patients who are \>40% above ideal weight will be dosed based on adjusted weight and adjusted BSA.~One day after the administration of cyclophosphamide, patients will receive sirolimus 6 mg PO x 1 and on the following day will start sirolimus at a dose of 2 mg PO daily.
Study: NCT01453140
Drug: Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza). The Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.~The dose administered will be 10 mg SQ daily for 5 days followed by 3 weeks off.
Study: NCT01453140
Drug: Cyclophosphamide and Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day 1: Cyclophosphamide Day 2: Sirolimus
Study: NCT01899027
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
Study: NCT01899027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive two overnight doses of Placebo 12 h before RNA and another dose 2 h before the procedure
Study: NCT04501276
Drug: ADG116
Approvals — FDA: no, EMA: no, PMDA: no
Description: For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
Study: NCT04501276
Drug: ADG106
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
Study: NCT00756249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vials with solution for IV infusion
Study: NCT01485094
Drug: GRT6010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution given once daily.
Study: NCT01485094
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo capsules to the over-encapsulated Pregabalin capsules and Matching Placebo oral solution to the GRT6010 solution.~Capsules twice daily on Days 1 to 7. Solution once daily.
Study: NCT01100658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule per day for 1 week.
Study: NCT05032287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT04331210
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group 1 will take oral diclofenac sodium and group 2 will take Rectal diclofenac sodium as an analgesic
Study: NCT00839436
Drug: CYT107
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03061474
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
Study: NCT03061474
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT03516604
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, identical to PF-04995274 tablet
Study: NCT03516604
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, identical to citalopram capsule
Study: NCT04301466
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks.To preserve blinding, the placebo had an identical taste and appearance to the experimental drugs. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
Study: NCT01291511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules were administered orally using a bid schedule during the double-blind period.
Study: NCT02497924
Drug: GBT440
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBT440 capsules followed by single dose of \[C14\] GBT440 oral suspension
Study: NCT01246427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
Study: NCT03257813
Drug: PRO-122
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop every 12 hours for 30 days of alternating treatment with 30 days
Study: NCT03257813
Drug: Krytantek Ofteno®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop every 12 hours for 30 days of alternating treatment with 30 days
Study: NCT04402957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution
Study: NCT03445884
Drug: 68Ga-NODAGA-E[c(RGDyK)]2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.
Study: NCT02299726
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02795117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02576639
Drug: CNP520
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02576639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to CNP520 was supplied in capsules.
Study: NCT03615924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~* \>48 kg: Placebo to match ticagrelor 45 mg, twice a day.
Study: NCT03778099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg of starch and 50 mg of cinnamon powder
Study: NCT04617652
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 10 ml of saline, then infusion of 50 ml of normal saline over one hour.
Study: NCT04201249
Drug: Piroxicam, lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
Study: NCT00518869
Drug: PG2
Normalized name: Fossaoprin SPG2 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.
Study: NCT01511172
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin placebo administered orally. 1000 mg daily
Study: NCT01511172
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
Study: NCT00047593
Drug: IOP Lowering Medications
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01932450
Drug: antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
Study: NCT00475319
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different dosages of drug
Study: NCT00475319
Drug: 1% OPC-12759 ophthalmic suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different dosages of drug
Study: NCT00475319
Drug: 2% OPC-12759 ophthalmic suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different dosages of drug
Study: NCT02203630
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
Study: NCT01184508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily, for 12 weeks
Study: NCT01184508
Drug: LY2300559
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 milligrams (mg) administered orally, once daily, for 12 weeks
Study: NCT01122602
Drug: Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of fast acting aspirin 2 x 325 mg = 650 mg total
Study: NCT01122602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo tablets
Study: NCT04810793
Drug: Tetracycline , Furazolidone and Esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens
Study: NCT04810793
Drug: Tetracycline,Furazolidone and Vonoprazan fumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group
Study: NCT03684265
Drug: Meloxicam Capsule (Test)
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose
Study: NCT03684265
Drug: Meloxicam Tablet (Reference)
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose
Study: NCT04820439
Drug: recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous infusion of HS627 420mg
Study: NCT04820439
Drug: Perjeta ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous infusion of Perjeta ®420mg
Study: NCT03630224
Drug: Plasmalyte Viaflo
Normalized name: Plasmalyte A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
Study: NCT03721341
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy may be given as indicated.
Study: NCT03721341
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy may be given as indicated.
Study: NCT03721341
Drug: Hormones
Normalized name: Other hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormones may be given as indicated.
Study: NCT02394535
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01900795
Drug: V117957
Approvals — FDA: no, EMA: no, PMDA: no
Description: V117957 4.5 mg suspension taken orally after surgery.
Study: NCT01900795
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400 mg tablets taken orally after surgery.
Study: NCT01900795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken orally after surgery.
Study: NCT03630224
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
Study: NCT03247543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered once daily
Study: NCT03247543
Drug: 400mg SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg SPN-812 was administered once daily and compared to placebo
Study: NCT02762136
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02762136
Drug: Xiang-sha-liu-jun granules
Normalized name: Calagel Reformulated Jun 2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Xiang-sha-liu-jun granules comprises 10 herbs, Astragalus membranaceus (Huangqi) 15g, Codonopsis pilosula (Dangshen) 15 g, fructus aurantii (Zhiqiao) 15g, fructus amomi(Sharen) etc
Study: NCT00751075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
Study: NCT02366351
Drug: SHR3824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, 12 weeks
Study: NCT02366351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, 12 weeks
Study: NCT01653756
Drug: IPI-145, a PI3K Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug
Study: NCT02537249
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo infusion will be adjusted the same fashion as the active comparator drug.